Protein modifications involved in neurotransmitter and gasotransmitter signaling

Trends in Neurosciences

Volumn 33, Issue 11, 2010, Pages 493-502

  Sen, Nilkantha ^a   Snyder, Solomon H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CYCLIC AMP; CYSTEINE; HYDROGEN SULFIDE; LYSINE; MEMBRANE RECEPTOR; NEUROTRANSMITTER; NITRIC OXIDE;

ACETYLATION; NEUROTRANSMISSION; NITROSYLATION; PALMITOYLATION; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; REVIEW; SECOND MESSENGER; SUMOYLATION;

ANIMALS; HUMANS; NEUROTRANSMITTER AGENTS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEINS; SIGNAL TRANSDUCTION;

EID: 77958158351     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2010.07.004     Document Type: Review

References (120)

1. Garthwaite J. New insight into the functioning of nitric oxide-receptive guanylyl cyclase: physiological and pharmacological implications. Mol. Cell Biochem. 2010, 334:221-232.
2. Jaffrey S.R., et al. CAPON: a protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95. Neuron 1998, 20:115-124.
3. Mustafa A.K. H2S signals through protein S-sulfhydration. Sci. Signal. 2009, 2:ra72.
4. Prescott G.R., et al. Palmitoylation of the synaptic vesicle fusion machinery. J. Neurochem. 2009, 110:1135-1149.
5. Sterner D.E., Berger S.L. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 2000, 64:435-459.
6. Spange S., et al. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell Biol. 2009, 41:185-198.
7. Anderson D.B., et al. Protein SUMOylation in neuropathological conditions. Drug News Perspect. 2009, 22:255-265.
8. Hess D.T., et al. Protein S-nitrosylation: purview and parameters. Nat. Rev. Mol. Cell Biol. 2005, 6:150-166.
9. Jaffrey S.R., et al. Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat. Cell Biol. 2001, 3:193-197.
10. Choi Y.B., et al. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat. Neurosci. 2000, 3:15-21.
11. Brenman J.E., et al. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell 1996, 84:757-767.
12. Zhou L., Zhu D.Y. Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide 2009, 20:223-230.
13. Lipton S.A., et al. Cysteine regulation of protein function - as exemplified by NMDA-receptor modulation. Trends Neurosci. 2002, 25:474-480.
14. Derkach V.A., et al. Regulatory mechanisms of AMPA receptors in synaptic plasticity. Nat. Rev. Neurosci. 2007, 8:101-113.
15. Kullmann D.M., et al. LTP of AMPA and NMDA receptor-mediated signals: evidence for presynaptic expression and extrasynaptic glutamate spill-over. Neuron 1996, 17:461-474.
16. Shepherd J.D., Huganir R.L. The cell biology of synaptic plasticity: AMPA receptor trafficking. Annu. Rev. Cell Dev. Biol. 2007, 23:613-643.
17. Huang Y., et al. S-nitrosylation of N-ethylmaleimide sensitive factor mediates surface expression of AMPA receptors. Neuron 2005, 46:533-540.
18. Chen L., et al. Stargazin regulates synaptic targeting of AMPA receptors by two distinct mechanisms. Nature 2000, 408:936-943.
19. Selvakumar B., et al. S-nitrosylation of stargazin regulates surface expression of AMPA-glutamate neurotransmitter receptors. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:16440-16445.
20. Mustafa A.K., et al. Nitric oxide S-nitrosylates serine racemase, mediating feedback inhibition of D-serine formation. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:2950-2955.
21. Kemppainen R.J., Behrend E.N. Dexamethasone rapidly induces a novel ras superfamily member-related gene in AtT-20 cells. J. Biol. Chem. 1998, 273:3129-3131.
22. Fang M., et al. Dexras1: a G protein specifically coupled to neuronal nitric oxide synthase via CAPON. Neuron 2000, 28:183-193.
23. Cheah J.H., et al. NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase Dexras1. Neuron 2006, 51:431-440.
24. Huang P.L., et al. Nitric oxide and cerebral ischemic preconditioning. Cell Calcium 2004, 36:323-329.
25. Hara M.R., et al. S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nat. Cell Biol. 2005, 7:665-674.
26. Sen N., et al. GOSPEL: a neuroprotective protein that binds to GAPDH upon S-nitrosylation. Neuron 2009, 63:81-91.
27. Hara M.R., et al. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:3887-3889.
28. Chung K.K., et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 2004, 304:1328-1331.
29. Yao D., et al. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10810-10814.
30. Jourd'heuil D., et al. Effect of superoxide dismutase on the stability of S-nitrosothiols. Arch. Biochem. Biophys. 1999, 361:323-330.
31. Benhar M., et al. Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins. Science 2008, 320:1050-1054.
32. Uehara T., et al. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 2006, 441:513-517.
33. Cho D.H., et al. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 2009, 324:102-105.
34. Kim S.F., et al. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005, 310:1966-1970.
35. Tian J., et al. S-nitrosylation/activation of COX-2 mediates NMDA neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10537-10540.
36. Meffert M.K., Baltimore D. Physiological functions for brain NF-kappaB. Trends Neurosci. 2005, 28:37-43.
37. Yu Z., et al. Lack of the p50 subunit of nuclear factor-kappaB increases the vulnerability of hippocampal neurons to excitotoxic injury. J. Neurosci. 1999, 19:8856-8865.
38. Meffert M.K., et al. NF-kappa B functions in synaptic signaling and behavior. Nat. Neurosci. 2003, 6:1072-1078.
39. Guerrini L., et al. Synaptic activation of NF-kappa B by glutamate in cerebellar granule neurons in vitro. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:9077-9081.
40. Marshall H.E., et al. S-nitrosylation: physiological regulation of NF-kappaB. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:8841-8842.
41. Kimura H., et al. Physiological roles of hydrogen sulfide: synaptic modulation, neuroprotection, and smooth muscle relaxation. Antioxid. Redox Signal. 2005, 7:795-803.
42. Pereira S.G., Oakley F. Nuclear factor-kappaB1: regulation and function. Int. J. Biochem. Cell Biol. 2008, 40:1425-1430.
43. Szabó C. Hydrogen sulphide and its therapeutic potential. Nat. Rev. Drug Discov. 2007, 6:917-935.
44. Wang R. Hydrogen sulfide: a new EDRF. Kidney Int. 2009, 76:700-704.
45. 2S) - the third gas of interest for pharmacologists. Pharmacol. Rep. 2007, 59:4-24.
46. Mancardi D., et al. Physiological and pharmacological features of the novel gasotransmitter: hydrogen sulfide. Biochim. Biophys. Acta 2009, 1787:864-872.
47. Yang G., et al. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 2008, 322:587-590.
48. Abe K., Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J. Neurosci. 1996, 16:1066-1071.
49. Kimura H., et al. Physiological roles of hydrogen sulfide: synaptic modulation, neuroprotection, and smooth muscle relaxation. Antioxid. Redox Signal. 2005, 7:795-803.
50. Nagai Y., et al. Hydrogen sulfide induces calcium waves in astrocytes. FASEB J. 2004, 18:557-559.
51. Kimura Y., Kimura H. Hydrogen sulfide protects neurons from oxidative stress. FASEB J. 2004, 18:1165-1167.
52. Warenycia M.W. Monoamine oxidase inhibition as a sequel of hydrogen sulfide intoxication: increases in brain catecholamine and 5-hydroxytryptamine levels. Arch. Toxicol. 1989, 63:131-136.
53. Han Y., et al. Hydrogen sulfide may improve the hippocampal damage induced by recurrent febrile seizures in rats. Biochem. Biophys. Res. Commun. 2005, 327:431-436.
54. Hu L.F., et al. Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models. Aging Cell 2010, 9:135-146.
55. Mustafa A.K., et al. Signaling by gasotransmitters. Sci. Signal. 2009, 2:re2.
56. Zhang F.L., Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 1996, 65:241-269.
57. Johnson D.R., et al. Genetic and biochemical studies of protein N-myristoylation. Annu. Rev. Biochem. 1994, 63:869-914.
58. Parpura V., Mohideen U. Molecular form follows function: (un)snaring the SNAREs. Trends Neurosci. 2008, 31:435-443.
59. Hess D.T., et al. The 25 kDa synaptosomal-associated protein SNAP-25 is the major methionine-rich polypeptide in rapid axonal transport and a major substrate for palmitoylation in adult CNS. J. Neurosci. 1992, 12:4634-4641.
60. Kang R., et al. Neural palmitoyl-proteomics reveals dynamic synaptic palmitoylation. Nature 2008, 456:904-909.
61. Heindel U., et al. Palmitoylation sites and processing of synaptotagmin I, the putative calcium sensor for neurosecretion. FEBS Lett. 2003, 544:57-62.
62. Martin B.R., Cravatt B.F. Large-scale profiling of protein palmitoylation in mammalian cells. Nat. Methods 2009, 6:135-138.
63. Resh M.D. Palmitoylation of ligands, receptors, and intracellular signaling molecules. Sci. STKE 2006, 2006:re14.
64. Degtyarev M.Y., et al. Increased palmitoylation of the Gs protein alpha subunit after activation by the beta-adrenergic receptor or cholera toxin. J. Biol. Chem. 1993, 268:23769-23772.
65. Linder M.E., et al. Lipid modifications of G proteins: alpha subunits are palmitoylated. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:3675-3679.
66. O'Dowd B.F., et al. Palmitoylation of the human beta 2-adrenergic receptor. Mutation of Cys341 in the carboxyl tail leads to an uncoupled nonpalmitoylated form of the receptor. J. Biol. Chem. 1989, 264:7564-7569.
67. Loisel T.P., et al. Activation of the beta(2)-adrenergic receptor-Galpha(s) complex leads to rapid depalmitoylation and inhibition of repalmitoylation of both the receptor and Galpha(s). J. Biol. Chem. 1999, 274:31014-31019.
68. Hayashi T., et al. Dual palmitoylation of NR2 subunits regulates NMDA receptor trafficking. Neuron 2009, 64:213-226.
69. Hayashi T., et al. Differential regulation of AMPA receptor subunit trafficking by palmitoylation of two distinct sites. Neuron 2005, 47:709-723.
70. Fukata M. Identification of PSD-95 palmitoylating enzymes. Neuron 2004, 44:987-996.
71. Topinka J.R., Bredt D.S. N-terminal palmitoylation of PSD-95 regulates association with cell membranes and interaction with K+ channel Kv1.4. Neuron 1998, 20:125-134.
72. El-Husseini A., et al. Synaptic strength regulated by palmitate cycling on PSD-95. Cell 2002, 108:849-863.
73. Kang R., et al. Presynaptic trafficking of synaptotagmin I is regulated by protein palmitoylation. J. Biol. Chem. 2004, 279:50524-50536.
74. Noritake J., et al. Mobile DHHC palmitoylating enzyme mediates activity-sensitive synaptic targeting of PSD-95. J. Cell Biol. 2009, 186:147-160.
75. Fukata Y., Fukata M. Protein palmitoylation in neuronal development and synaptic plasticity. Nat. Rev. Neurosci. 2010, 11:161-175.
76. Fang C., et al. GODZ-mediated palmitoylation of GABA(A) receptors is required for normal assembly and function of GABAergic inhibitory synapses. J. Neurosci. 2006, 26:12758-12768.
77. Biljmakers M.J., Marsh M. The on-off story of protein palmitoylation. Trends Cell Biol. 2003, 13:32-42.
78. Chow E.W., et al. Neurocognitive profile in 22q11 deletion syndrome and schizophrenia. Schizophr. Res. 2006, 87:270-278.
79. Pulver A.E., et al. Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives. J. Nerv. Ment. Dis. 1994, 182:476-478.
80. Edelmann L., et al. Low-copy repeats mediate the common 3-Mb deletion in patients with velo-cardio-facial syndrome. Am. J. Hum. Genet. 1999, 64:1076-1086.
81. Mukai J., et al. Palmitoylation-dependent neurodevelopmental deficits in a mouse model of 22q11 microdeletion. Nat. Neurosci. 2008, 11:1302-1310.
82. Huang K., et al. Neuronal palmitoyl acyl transferases exhibit distinct substrate specificity. FASEB J. 2009, 23:2605-2615.
83. Yanai A., et al. Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function. Nat. Neurosci. 2006, 9:824-831.
84. Halpain S., et al. Regulation of F-actin stability in dendritic spines by glutamate receptors and calcineurin. J. Neurosci. 1998, 18:9835-9844.
85. Heun P. SUMOrganization of the nucleus. Curr. Opin. Cell Biol. 2007, 19:350-355.
86. Geiss-Friedlander R., Melchior F. Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 2007, 8:947-956.
87. Zhao J. Sumoylation regulates diverse biological processes. Cell. Mol. Life Sci. 2007, 64:3017-3033.
88. Mukhopadhyay D., Dasso M. Modification in reverse: the SUMO proteases. Trends Biochem. Sci. 2007, 32:286-295.
89. Kahyo T., et al. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol. Cell 2001, 8:713-718.
90. Pichler A., et al. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 2002, 108:109-120.
91. Kagey M.H., et al. The polycomb protein Pc2 is a SUMO E3. Cell 2003, 113:127-137.
92. Martin S., et al. Emerging extranuclear roles of protein SUMOylation in neuronal function and dysfunction. Nat. Rev. Neurosci. 2007, 8:948-959.
93. Shalizi A.K., Bonni A. brawn for brains: the role of MEF2 proteins in the developing nervous system. Curr. Top. Dev. Biol. 2005, 69:239-266.
94. Shalizi A., et al. A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science 2006, 311:1012-1017.
95. Wilson V.G., Rosas-Acosta G. Wrestling with SUMO in a new arena. Sci. STKE 2005, 2005:pe32.
96. Plant L.D., et al. K2P channels and their protein partners. Curr. Opin. Neurobiol. 2005, 15:326-333.
97. Pannasch U., et al. The potassium channels Kv1.5 and Kv1.3 modulate distinct functions of microglia. Mol. Cell. Neurosci. 2006, 33:401-411.
98. Benson M.D., et al. SUMO modification regulates inactivation of the voltage-gated potassium channel Kv1.5. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:1805-1810.
99. Martin S., et al. SUMOylation regulates kainate-receptor-mediated synaptic transmission. Nature 2007, 447:321-325.
100. Rosas H.D., et al. Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease?. Ann. N. Y. Acad. Sci. 2008, 1147:196-205.
101. Steffan J.S., et al. SUMO modification of Huntingtin and Huntington's disease pathology. Science 2004, 304:100-104.
102. Subramaniam S., et al. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 2009, 324:1327-1330.
103. Subramaniam S., et al. Rhes, a physiologic regulator of sumoylation, enhances cross-sumoylation between e1 and ubc9. J. Biol. Chem. 2010, 285:20428-20432.
104. Okamoto S., et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 2009, 15:1407-1413.
105. Riley B.E., et al. SUMOylation of the polyglutamine repeat protein, ataxin-1, is dependent on a functional nuclear localization signal. J. Biol. Chem. 2005, 280:21942-21948.
106. Zoghbi H.Y., Orr H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 2000, 23:217-247.
107. Dorval V., Fraser P.E. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. J. Biol. Chem. 2006, 281:9919-9924.
108. Um J.W., Chung K.C. Functional modulation of parkin through physical interaction with SUMO-1. J. Neurosci. Res. 2006, 84:1543-1554.
109. Um J.W., et al. Parkin ubiquitinates and promotes the degradation of RanBP2. J. Biol. Chem. 2006, 281:3595-3603.
110. Abou-Sleiman P.M., et al. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 2006, 7:207-219.
111. Shinbo Y., et al. Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities. Cell Death Differ. 2006, 13:96-108.
112. Covington H.E., 3rd, et al. Antidepressant actions of histone deacetylase inhibitors. J. Neurosci. 2009, 29:11451-11460.
113. Butler R., Bates G.P. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat. Rev. Neurosci. 2006, 7:784-796.
114. Chen B., Cepko C.L. HDAC4 regulates neuronal survival in normal and diseased retinas. Science 2009, 323:256-259.
115. Huang E., Reichardt L. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 2001, 24:677-736.
116. Nott A., et al. S-Nitrosylation of histone deacetylase 2 induces chromatin remodelling in neurons. Nature 2008, 455:411-415.
117. Choudhary C., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
118. Sen N., et al. Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat. Cell Biol. 2008, 10:866-873.
119. Jeong H., et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 2009, 137:60-72.
120. Li F., et al. Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J. Biol. Chem. 2002, 277:45004-45012.